Business
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Company to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central White Paper: The Potential of DM199 to Treat Preeclampsia
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":"\n\nCompany to Host Preeclampsia Key Opinion Leader Event July 29, 2024 at 10 AM Eastern / 9 AM Central\n\n\n\nWhite Paper: The Potential of DM199 to Treat Preeclampsia\n\n\n\n MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced that it will host a virtual key opinion leader (KOL) event on Monday, July 29, 2024, at 10:00 AM ET to provide further insight into the expansion of its clinical development program for DM199 (rinvecalinase alfa) into preeclampsia, a significant, unmet medical need with no FDA-approved therapeutics.\n\n\nThe webinar will feature Prof. Stephen Tong, MD, PhD (The University of Melbourne), Prof. Catherine Cluver, MD, PhD (Stellenbosch University), and Prof. Susan Walker, MD, PhD (The University of Melbourne) who will discuss the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. This will be followed by a discussion on the uniquely on-target mechanism of action of DM199 (rinvecalinase alfa) as a potential treatment for PE, and the upcoming Phase 2, proof-of-concept, clinical trial of DM199 in PE anticipated to commence enrollment in the fourth quarter of 2024.\n\n\nThe event will focus on the rationale for DiaMedica's expansion of its DM199 (recombinant human tissue kallikrein-1 (rhKLK1)) clinical development program and provide an overview of the Phase 2 investigator-sponsored trial in preeclampsia and fetal growth restriction. DM199, through enhancing the body’s natural ability to produce nitric oxide, prostacyclin and endothelium-derived hyper polarizing factor, has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.\n\n\nA live question and answer session will follow the formal presentations.\n\n\nTo register, click here.\n\n\nWhite Paper: The Potential of DM199 to Treat Preeclampsia\n\n\nIn conjunction with the webinar, DiaMedica is releasing a white paper titled “The Potential of DM199 to Treat Preeclampsia”. The white paper can be downloaded from the Literature & Publications section of DiaMedica.com or, click here.\n\n\nAbout Professor Stephen Tong\n\n\nProfessor Stephen Tong i...